25.04 USD
+0.23 (+0.93%)
25.04 USD
0 (0%)
Taking everything into account, ACAD scores 5 out of 10 in our fundamental rating. ACAD was compared to 533 industry peers in the Biotechnology industry. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ACAD is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ACAD was profitable.
In the past year ACAD had a positive cash flow from operations.
ACAD had negative earnings in each of the past 5 years.
ACAD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ACAD's Return On Assets of 19.63% is amongst the best of the industry. ACAD outperforms 96.81% of its industry peers.
ACAD has a better Return On Equity (28.47%) than 97.37% of its industry peers.
The Return On Invested Capital of ACAD (7.66%) is better than 93.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROIC | 7.66% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACAD's Profit Margin of 24.94% is amongst the best of the industry. ACAD outperforms 95.31% of its industry peers.
Looking at the Operating Margin, with a value of 9.02%, ACAD belongs to the top of the industry, outperforming 91.37% of the companies in the same industry.
ACAD has a Gross Margin of 91.92%. This is amongst the best in the industry. ACAD outperforms 92.50% of its industry peers.
ACAD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ACAD is destroying value.
Compared to 1 year ago, ACAD has more shares outstanding
The number of shares outstanding for ACAD has been increased compared to 5 years ago.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ACAD has an Altman-Z score of 5.55. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
ACAD has a better Altman-Z score (5.55) than 75.61% of its industry peers.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.55 |
ROIC/WACC0.88
WACC8.66%
2.3 Liquidity
A Current Ratio of 3.02 indicates that ACAD has no problem at all paying its short term obligations.
The Current ratio of ACAD (3.02) is worse than 63.04% of its industry peers.
A Quick Ratio of 2.94 indicates that ACAD has no problem at all paying its short term obligations.
The Quick ratio of ACAD (2.94) is worse than 61.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 |
3. Growth
3.1 Past
The earnings per share for ACAD have decreased strongly by -14.10% in the last year.
The Revenue has grown by 121.75% in the past year. This is a very strong growth!
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
3.2 Future
ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.38% yearly.
ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.84% yearly.
EPS Next Y21.55%
EPS Next 2Y35.04%
EPS Next 3Y37.81%
EPS Next 5Y39.38%
Revenue Next Year10.06%
Revenue Next 2Y10.93%
Revenue Next 3Y10.69%
Revenue Next 5Y9.84%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 37.37 indicates a quite expensive valuation of ACAD.
Based on the Price/Earnings ratio, ACAD is valued cheaper than 91.18% of the companies in the same industry.
ACAD's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.31.
The Price/Forward Earnings ratio is 28.61, which means the current valuation is very expensive for ACAD.
Based on the Price/Forward Earnings ratio, ACAD is valued cheaper than 91.37% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ACAD to the average of the S&P500 Index (36.59), we can say ACAD is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.37 | ||
| Fwd PE | 28.61 |
4.2 Price Multiples
93.06% of the companies in the same industry are more expensive than ACAD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ACAD is valued cheaper than 94.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.4 | ||
| EV/EBITDA | 25.35 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ACAD may justify a higher PE ratio.
ACAD's earnings are expected to grow with 37.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.73
PEG (5Y)N/A
EPS Next 2Y35.04%
EPS Next 3Y37.81%
5. Dividend
5.1 Amount
ACAD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
25.04
+0.23 (+0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.78%
Inst Owner Change1.37%
Ins Owners0.3%
Ins Owner Change0.15%
Market Cap4.22B
Revenue(TTM)1.05B
Net Income(TTM)261.17M
Analysts77.04
Price Target29.41 (17.45%)
Short Float %5.07%
Short Ratio4.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.34%
Min EPS beat(2)14.46%
Max EPS beat(2)178.22%
EPS beat(4)2
Avg EPS beat(4)20.1%
Min EPS beat(4)-109.07%
Max EPS beat(4)178.22%
EPS beat(8)5
Avg EPS beat(8)29%
EPS beat(12)7
Avg EPS beat(12)26.97%
EPS beat(16)10
Avg EPS beat(16)24.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)6
Avg Revenue beat(16)-1.45%
PT rev (1m)-0.77%
PT rev (3m)-2.99%
EPS NQ rev (1m)15.12%
EPS NQ rev (3m)21.84%
EPS NY rev (1m)-1.41%
EPS NY rev (3m)1.31%
Revenue NQ rev (1m)2.27%
Revenue NQ rev (3m)2.24%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)0.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.37 | ||
| Fwd PE | 28.61 | ||
| P/S | 4.03 | ||
| P/FCF | 19.4 | ||
| P/OCF | 13.3 | ||
| P/B | 4.61 | ||
| P/tB | 5.24 | ||
| EV/EBITDA | 25.35 |
EPS(TTM)0.67
EY2.68%
EPS(NY)0.88
Fwd EY3.5%
FCF(TTM)1.29
FCFY5.15%
OCF(TTM)1.88
OCFY7.52%
SpS6.21
BVpS5.44
TBVpS4.78
PEG (NY)1.73
PEG (5Y)N/A
Graham Number9.05
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROCE | 9.69% | ||
| ROIC | 7.66% | ||
| ROICexc | 58.65% | ||
| ROICexgc | 479.54% | ||
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% | ||
| FCFM | 20.79% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score4
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 711.57% | ||
| Cap/Sales | 9.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 292.92% | ||
| Profit Quality | 83.36% | ||
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 | ||
| Altman-Z | 5.55 |
F-Score4
WACC8.66%
ROIC/WACC0.88
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y21.55%
EPS Next 2Y35.04%
EPS Next 3Y37.81%
EPS Next 5Y39.38%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year10.06%
Revenue Next 2Y10.93%
Revenue Next 3Y10.69%
Revenue Next 5Y9.84%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.53%
EBIT Next 3Y32.73%
EBIT Next 5Y43.57%
FCF growth 1Y264.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y443.26%
OCF growth 3YN/A
OCF growth 5YN/A
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the ChartMill fundamental rating of ACADIA PHARMACEUTICALS INC (ACAD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ACAD.
Can you provide the valuation status for ACADIA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.
Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?
ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.
What is the earnings growth outlook for ACADIA PHARMACEUTICALS INC?
The Earnings per Share (EPS) of ACADIA PHARMACEUTICALS INC (ACAD) is expected to grow by 21.55% in the next year.